Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07802405 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis

Name: Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis — clinical trial record (NCT07802405)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorHenan Cancer Hospital

Started2023-11-21

View on ClinicalTrials.gov ↗

Record status

This record was last updated September 3, 2026 (before its estimated September 26, 2026 completion). Its status may not reflect the trial's current state.

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

This is a Phase I clinical study to evaluate the safety and tolerability, pharmacokinetic characteristics and preliminary efficacy of oral WJ01024 administered as monotherapy and in combination with ruxolitinib in patients with myelofibrosis（MF）. The study will be conducted in two phases: Phase IA and Phase IB. Phase IA is a dose-escalation and dose-expansion study of WJ01024 monotherapy in patients with MF after failure of JAK inhibitor (JAKi) therapy (relapsed/refractory/intolerant). Phase IB is a dose-escalation and dose-expansion study of WJ01024 in combination with ruxolitinib in JAKi-naïve patients with intermediate- or high-risk MF.

Trial Details

NCT Number	NCT07802405
Lead Sponsor	Henan Cancer Hospital
Conditions	MF With Splenomegaly
Enrollment	20 participants
Start Date	2023-11-21
Primary Completion	2026-09-26 (estimated)
Study Completion	2027-11-21 (estimated)
Updated on ClinicalTrials.gov	2026-09-03